Human Pluripotent Stem Cell-Derived Mesenchymal Stem Cells for Oncotherapy

Abstract

Mesenchymal stem/stromal cells (MSCs) with hematopoietic-supporting and immunoregulatory properties have aroused great expectations in the field of regenerative medicine and the concomitant pathogenesis. However, many obstacles still remain before the large-scale preparation of homogeneous and standardized MSCs with high cellular vitality for clinical purposes ascribe to elusive nature and biofunction of MSCs derived from various adult and fetal sources. Current progress in human pluripotent stem cells (hPSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), have highlighted the feasibility of MSC development and disease remodeling, together with robust MSC generation dispense from the inherent disadvantages of the aforementioned MSCs including ethical and pathogenic risks, donor heterogeneity and invasiveness. Herein, we review the state-of-the-art updates of advances for MSC preparation from hPSCs and multiple tissues (perinatal tissue, adult tissue) as well as tumor intervention with biomaterials, and thus propose a framework for MSCs-based oncotherapy in regenerative medicine. Collectively, we describe the landscape of in vitro generation and functional hierarchical organization of hPSC-MSCs, which will supply overwhelming new references for further dissecting MSC-based tissue engineering and disease remodeling.